Loading
CASR (Extracellular calcium-sensing receptor) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
G protein-coupled receptor that senses changes in the extracellular concentration of calcium ions and plays a key role in maintaining calcium homeostasis. Senses fluctuations in the circulating calcium concentration: activated by elevated circulating calcium, leading to decreased parathyroid hormone (PTH) secretion in parathyroid glands. In kidneys, acts as a key regulator of renal tubular calcium resorption.
Open Targets scores its association with cancer at 0.61 (direct and indirect evidence; datatypes clinical 0.91, literature 0.98, genetic association 0.00, somatic mutation 0.23, animal model 0.59).
In plain words · CASR (Extracellular calcium-sensing receptor) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
CASR (Extracellular calcium-sensing receptor) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
G protein-coupled receptor that senses changes in the extracellular concentration of calcium ions and plays a key role in maintaining calcium homeostasis.
No product in this corpus aims at CASR yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enriched, which says where the protein sits but not whether the tumour differs from normal tissue. HPA CASR: RNA tissue enriched (parathyroid gland 616 nTPM); high antibody staining in 3 normal tissues. Distribution: no corpus cancer carries a prevalence row, threshold or catalogue link for it; Open Targets associates it with 2 specific cancer types at or above 0.5 (neonatal severe primary hyperparathyroidism, parathyroid gland carcinoma). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas CASR tissue; Open Targets ENSG00000036828 associations
First described 1995. Earliest sequence paper UniProt cites for the protein: Garrett J.E. et al, J. Biol. Chem, 1995, "Molecular cloning and functional expression of human parathyroid calcium receptor cDNAs". Source.
Sources: HGNC HGNC:1514 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P41180 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000036828 (association with cancer (MONDO_0004992) 0.61; (GraphQL API, CC0))
G protein-coupled receptor that senses changes in the extracellular concentration of calcium ions and plays a key role in maintaining calcium homeostasis. Senses fluctuations in the circulating calcium concentration: activated by elevated circulating calcium, leading to decreased parathyroid hormone (PTH) secretion in parathyroid glands. In kidneys, acts as a key regulator of renal tubular calcium resorption. Ligand binding causes a conformation change that triggers signalling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors. CASR is coupled with different G(q)/G(11), G(i)/G(o)- or G(s)-classes of G proteins depending on the context. In the parathyroid and kidney, CASR signals through G(q)/G(11) and G(i)/G(o) G proteins: G(q)/G(11) coupling activates phospholipase C-beta, releasing diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) second messengers, while G(i)/G(o) coupling mediates inhibition of adenylate cyclase activity. Location: Cell membrane (UniProt). Locus 3q13.33-q21.1 (HGNC).
RNA: tissue enriched (parathyroid gland 616 nTPM), detected in some normal tissues.
RNA cancer enhanced: Kidney Chromophobe 4 pTPM, Pancreatic Adenocarcinoma 8 pTPM.
No cancer stained high; medium in urothelial cancer.
HPA CASR tissue · HPA CASR pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"CASR" OR ABSTRACT:"CASR" OR TITLE:"calcium sensing receptor" OR ABSTRACT:"calcium sensing receptor" OR TITLE:"Extracellular calcium-sensing receptor" OR ABSTRACT:"Extracellular calcium-sensing receptor" OR TITLE:"NSHPT" OR ABSTRACT:"NSHPT" OR TITLE:"GPRC2A" OR ABSTRACT:"GPRC2A" OR TITLE:"HHC1" OR ABSTRACT:"HHC1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CASR, not a curated reading list.